Compare Stocks: MAIA, PRLD, BFNH, and FULC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFNH BioForce Nanosciences	$6.90 -1.0%	$6.32	$0.18 ▼ $10.99	$262.68M	0.63	8,497 shs	8,268 shs
FULC Fulcrum Therapeutics	$3.69 +0.4%	$3.79	$2.83 ▼ $15.74	$281.15M	2.63	1.62 million shs	653,105 shs
MAIA MAIA Biotechnology	$1.13 +0.9%	$1.31	$0.87 ▼ $3.19	$69.77M	0.27	762,548 shs	265,820 shs
PRLD Prelude Therapeutics	$3.36 +3.9%	$4.88	$1.16 ▼ $6.83	$267.34M	0.97	435,063 shs	249,440 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFNH BioForce Nanosciences	-6.57%	-21.60%	-28.22%	+364.67%	+747.42%
FULC Fulcrum Therapeutics	-0.27%	0.00%	-3.17%	+4.86%	-57.77%
MAIA MAIA Biotechnology	-3.45%	-5.08%	-19.42%	-15.79%	-23.81%
PRLD Prelude Therapeutics	-9.27%	-15.67%	-29.63%	-22.73%	+148.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFNH BioForce Nanosciences	$6.90 -1.0%	$6.32	$0.18 ▼ $10.99	$262.68M	0.63	8,497 shs	8,268 shs
FULC Fulcrum Therapeutics	$3.69 +0.4%	$3.79	$2.83 ▼ $15.74	$281.15M	2.63	1.62 million shs	653,105 shs
MAIA MAIA Biotechnology	$1.13 +0.9%	$1.31	$0.87 ▼ $3.19	$69.77M	0.27	762,548 shs	265,820 shs
PRLD Prelude Therapeutics	$3.36 +3.9%	$4.88	$1.16 ▼ $6.83	$267.34M	0.97	435,063 shs	249,440 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFNH BioForce Nanosciences	-6.57%	-21.60%	-28.22%	+364.67%	+747.42%
FULC Fulcrum Therapeutics	-0.27%	0.00%	-3.17%	+4.86%	-57.77%
MAIA MAIA Biotechnology	-3.45%	-5.08%	-19.42%	-15.79%	-23.81%
PRLD Prelude Therapeutics	-9.27%	-15.67%	-29.63%	-22.73%	+148.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFNH BioForce Nanosciences	0.00	N/A	N/A	N/A
FULC Fulcrum Therapeutics	1.75	Reduce	$8.20	122.52% Upside
MAIA MAIA Biotechnology	0.00	N/A	N/A	N/A
PRLD Prelude Therapeutics	2.57	Moderate Buy	$8.75	160.73% Upside

Current Analyst Ratings Breakdown

Latest MAIA, PRLD, BFNH, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/14/2026	PRLD Prelude Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/17/2026	PRLD Prelude Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$12.00
7/29/2026	PRLD Prelude Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
7/29/2026	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$8.00
7/17/2026	FULC Fulcrum Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
7/15/2026	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFNH BioForce Nanosciences	N/A	N/A	N/A	N/A	($0.02) per share	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	$6.45 per share	N/A
MAIA MAIA Biotechnology	N/A	N/A	N/A	N/A	$0.06 per share	N/A
PRLD Prelude Therapeutics	$22.42M	11.94	N/A	N/A	$1.09 per share	3.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFNH BioForce Nanosciences	-$1.29M	$0.01	690.69	N/A	N/A	N/A	-84.67%	-16.36%	N/A
FULC Fulcrum Therapeutics	-$74.88M	-$1.21	N/A	N/A	N/A	N/A	-25.38%	-24.15%	10/29/2026 (Estimated)
MAIA MAIA Biotechnology	-$22.40M	-$1.38	N/A	N/A	N/A	N/A	-211.15%	-126.26%	11/6/2026 (Estimated)
PRLD Prelude Therapeutics	-$99.50M	-$0.73	N/A	N/A	N/A	N/A	-75.35%	-44.39%	11/11/2026 (Estimated)

Latest MAIA, PRLD, BFNH, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	PRLD Prelude Therapeutics	$0.0040	N/A	N/A	N/A	$29.00 million	N/A
11/6/2026	Q3 2026	MAIA MAIA Biotechnology	-$0.13	N/A	N/A	N/A	N/A	N/A
10/29/2026	Q3 2026	FULC Fulcrum Therapeutics	-$0.0745	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	PRLD Prelude Therapeutics	-$0.1967	-$0.14	+$0.0567	-$0.14	$5.70 million	$5.70 million
8/10/2026	Q2 2026	BFNH BioForce Nanosciences	N/A	$0.01	N/A	$0.01	N/A	N/A
8/10/2026	Q2 2026	MAIA MAIA Biotechnology	-$0.11	-$0.13	-$0.02	-$0.13	N/A	N/A
7/30/2026	Q2 2026	FULC Fulcrum Therapeutics	-$0.2433	-$0.34	-$0.0967	-$0.34	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFNH BioForce Nanosciences	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
MAIA MAIA Biotechnology	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFNH BioForce Nanosciences	N/A	25.41	25.41
FULC Fulcrum Therapeutics	N/A	31.35	31.35
MAIA MAIA Biotechnology	N/A	4.51	4.51
PRLD Prelude Therapeutics	N/A	4.07	4.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFNH BioForce Nanosciences	N/A
FULC Fulcrum Therapeutics	89.83%
MAIA MAIA Biotechnology	5.65%
PRLD Prelude Therapeutics	79.72%

Insider Ownership

Company	Insider Ownership
BFNH BioForce Nanosciences	39.54%
FULC Fulcrum Therapeutics	7.30%
MAIA MAIA Biotechnology	19.81%
PRLD Prelude Therapeutics	49.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFNH BioForce Nanosciences	3	38.07 million	23.02 million	Not Optionable
FULC Fulcrum Therapeutics	55	76.30 million	70.73 million	Optionable
MAIA MAIA Biotechnology	13	61.74 million	49.51 million	Not Optionable
PRLD Prelude Therapeutics	79	79.80 million	40.54 million	Optionable

MAIA, PRLD, BFNH, and FULC Headlines

Recent News About These Companies

Prelude Therapeutics Incorporated Proceeds With Phase 1 Study Of PRT13722 In Patients With HR+/HER2- Breast Cancer

October 14 at 7:49 PM | marketscreener.comM

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in ...

October 13 at 8:59 AM | markets.businessinsider.com

Prelude, Lilly Partner On Breast Cancer Combination Trial; Stock Up

October 13 at 8:59 AM | rttnews.com

Prelude Therapeutics, Eli Lilly to Study Breast Cancer Drug Combinations in Phase 1 Trial

October 13 at 8:59 AM | finance.yahoo.com

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

October 13 at 7:01 AM | globenewswire.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock Rated "Moderate Buy" by Sell-Side Analysts

October 1, 2026 | marketbeat.com

Prelude Therapeutics stock gains as FDA clears new breast cancer drug trial

September 21, 2026 | ad-hoc-news.deA

Prelude Therapeutics (NASDAQ:PRLD) Stock Rating Lowered by Wall Street Zen

September 19, 2026 | marketbeat.com

JPMorgan Chase & Co. Initiates Coverage on Prelude Therapeutics (NASDAQ:PRLD)

September 17, 2026 | marketbeat.com

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 11, 2026 | globenewswire.com

Prelude Therapeutics, Incorporated: Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A ...

September 10, 2026 | finanznachrichten.de

Prelude Therapeutics Receives FDA Clearance For PRT13722 IND In HR+/HER2-Breast Cancer

September 10, 2026 | rttnews.com

Prelude Therapeutics Cleared by FDA for Phase 1 Breast Cancer Drug Trial

September 10, 2026 | finance.yahoo.com

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

September 10, 2026 | globenewswire.com

Prelude Therapeutics: A Prognosis After Year-Long Rally

August 23, 2026 | seekingalpha.com

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | markets.businessinsider.com

Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

July 31, 2026 | zacks.com

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why

July 17, 2026 | zacks.com

Prelude Therapeutics

July 14, 2026 | fool.com

Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 10, 2026 | seekingalpha.com

Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

May 16, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAIA, PRLD, BFNH, and FULC Company Descriptions

BioForce Nanosciences OTCMKTS:BFNH

$6.90 -0.07 (-1.00%)

As of 02:47 PM Eastern

BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. The company offers private label products with distributors and manufacturing providers. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, mass merchandisers, and online at www.bioforceeclipse.com, as well as through social media and telemarketing channels. BioForce Nanosciences Holdings, Inc. is based in Virginia Beach, Virginia.

Fulcrum Therapeutics NASDAQ:FULC

$3.68 +0.02 (+0.41%)

As of 03:19 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

MAIA Biotechnology NYSEAMERICAN:MAIA

$1.13 +0.01 (+0.89%)

As of 03:19 PM Eastern

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Prelude Therapeutics NASDAQ:PRLD

$3.36 +0.13 (+3.90%)

As of 03:18 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MAIA, PRLD, BFNH, and FULC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MAIA, PRLD, BFNH, and FULC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MAIA, PRLD, BFNH, and FULC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAIA, PRLD, BFNH, and FULC Company Descriptions

BioForce Nanosciences OTCMKTS:BFNH

Fulcrum Therapeutics NASDAQ:FULC

MAIA Biotechnology NYSEAMERICAN:MAIA

Prelude Therapeutics NASDAQ:PRLD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MAIA, PRLD, BFNH, and FULC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MAIA, PRLD, BFNH, and FULC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MAIA, PRLD, BFNH, and FULC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAIA, PRLD, BFNH, and FULC Company Descriptions

BioForce Nanosciences OTCMKTS:BFNH

Fulcrum Therapeutics NASDAQ:FULC

MAIA Biotechnology NYSEAMERICAN:MAIA

Prelude Therapeutics NASDAQ:PRLD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools